Disruptive mood dysregulation disorder — assessment, hierarchy, and management (MEQ)

(i) Assessment. Multi-informant: child, carers, school. Map outburst frequency/intensity/triggers and inter-outburst irritable mood with a 12-month timeline and multi-setting severity. Confirm chronological age ≥6, symptom onset before age 10, and no ≥3-month symptom-free period. Bipolar screen: distinct elevated/expansive periods, decreased need for sleep, grandiosity, goal-directed hyperactivity. Risk: aggression to peers/staff/siblings, weapons, self-harm, safeguarding. Comorbidity: ADHD (already suggested), learning, ASD traits, anxiety, trauma. Parenting ecology and coercive cycles. Competence/confidentiality principles and least-restrictive care — do not invent statute numbers.[4][1]

(ii) Diagnosis and differentials. Working diagnosis: DMDD with comorbid ADHD, family coercive conflict, school exclusion risk. Differentials: ODD (if both full criteria met → diagnose DMDD only); pediatric bipolar (no episodic manic features here); IED (lacks persistent inter-outburst irritable mood requirement); ADHD alone (does not capture full chronic multi-setting mood severity); trauma/ASD/medical. Discriminators: course (chronic vs episodic), multi-setting irritability, absence of mania, developmental history.[4][1][8]

(iii) Initial management. Safety/school behaviour plan; parent management training with consistency and de-escalation; child emotion-regulation skills; school liaison to prevent exclusion. Optimise ADHD treatment (stimulant pathway as indicated). Named psychosocial anchors: integrative parent–child group therapy after stimulant stabilisation (Waxmonsky SMD+ADHD trial logic); consider specialised skills packages (e.g. DBT-C evidence in preadolescent DMDD) where available. Measurement-based tracking of outbursts and attendance.[7][4]

(iv) Medication evidence. Do not start lithium as default "bipolar treatment" — Dickstein RCT found no meaningful lithium superiority over placebo in SMD. If residual severe irritability persists after stimulant optimisation and intensive psychosocial care, Towbin RCT supports considering adjunctive citalopram versus placebo on a stimulant background, with youth SSRI monitoring for activation/suicidality (e.g. start low such as citalopram 10 mg orally daily under specialist review). Antipsychotics only for severe aggression with time-limited goals and metabolic monitoring — not open-ended polypharmacy.[5][6]

(v) Prognosis message. Chronic severe irritability is impairing but is not inevitable bipolar disorder. Longitudinal work shows elevated risk of adult anxiety and depression and functional difficulties more than classic mania conversion; SMD follow-up shows rare manic episodes relative to narrow bipolar samples. Emphasise skills, school inclusion, and treating ADHD/family systems as trajectory-changing interventions.[3][8][2]